18-21 April 2016 Glasgow
![]() |
![]() |
![]() |
![]() |
42-P | Development of a long-acting granulocyte colony stimulating factor molecule | Hadel Ghaban | ![]() |
![]() |
|||
45-P | Impact of immunoparesis and altered serum free light chain ratio (ASFLCR) on the progression of monoclonal gammopathy of undetermined significance (MGUS ) in a district general hospital in the United Kingdom | Buddhika Badugama | ![]() |
![]() |
|||
46-P | Anti-coagulation DATIX incident reporting audit | Christopher Broadfield | ![]() |
![]() |
|||
47-P | Clinical pharmacist-provided services in iron overloaded beta-thalassemia major children; a new insight to patient care | Salma Bahnasawy | ![]() |
![]() |
|||
48-P | How do myeloma patients experiences before and during diagnosis compare to those for all cancers? Findings from secondary analysis of the National Cancer Patient Experience Survey 2014 | Sarah Richard | ![]() |
![]() |
|||
49-P | Assessing the applicability of a blood test guide in Accident and Emergency to optimise blood test requesting and achieve value for money | Assia Merzougui | ![]() |
![]() |
|||
51-P | Review of use and implementation of the 2015 BCSH guidelines for the prophylaxis and treatment of tumour lysis syndrome in patients with haematological malignancy at University Hospitals Bristol | Rebecca Oliver | ![]() |
![]() |
|||
54-P | EphB4 enhances bone marrow stromal stem cell-mediated support of haematopoiesis | Thao Nguyen | ![]() |
![]() |
|||
60-P | The clinical utility of reticulocyte haemoglobin equivalent (Ret-He) and red cell distribution width (RDW-CV) in patients with polycythaemia vera | Reginah Paradza | ![]() |
![]() |
|||
67-P | The Limitations of a Generic Chemotherapy Consent form: Improving Chemotherapy Consent with the Use of Regimen-Specific Consent Forms | Caroline Watson | ![]() |
![]() |
|||
68-P | The Latin American experience allografting patients with severe aplastic anaemia: Real-world data on the impact of stem cell source and ATG administration | Perla Colunga | ![]() |
![]() |
|||
71-P | Critical care of patients with haematological malignancies a retrospective analysis of one tertiary centres experience | Alasdair Duguid | ![]() |
![]() |
|||
72-P | A gain-of-function variant in DIAPH1 is associated with heritable macrothrombocytopenia and sensorineural deafness | Sarah Westbury | ![]() |
![]() |
|||
87-P | CellCountr: An online workspace for streamlining the interpretation of bone marrow aspirates - case study of use in a teaching hospital diagnostic laboratory. https://cellcountr.com | Duncan Brian | ![]() |
![]() |
|||
89-P | Age and gender effect on osteonecrosis in sickle cell disease | Hassan Al-Jafar | ![]() |
![]() |
|||
91-P | Reversal of coagulation markers in patients on dabigatran by prothrombin complex concentrate: A meta analysis | Bryony Rudd | ![]() |
![]() |
|||
92-P | Prevalence of genetic variations in SERPINC1 gene in Indian deep vein thrombosis population with type I antithrombin deficiency | TEENA BHAKUNI | ![]() |
![]() |
|||
94-P | Is there a need for a community anticoagulant monitoring service for the new direct acting oral anticoagulants? | David Rhead | ![]() |
![]() |
|||
100-P | Preventing hospital acquired thrombosis in medical patients at a district general hospital: Compliance with National Institute for Health and Care Excellence (NICE) guidance | Rosanna Ghinai | ![]() |
![]() |
|||
101-P | External quality assurance (EQA) for thromboelastography (TEG) and thromboelastometry (Rotem) | Dianne Kitchen | ![]() |
![]() |
|||
103-P | Validity of two-level Wells score in predicting lower limb deep vein thrombosis and the risk of developing hospital aquired thrombosis in hospitalised patients at National Hospital of Sri Lanka | Nadishani Ediriwickrama | ![]() |
![]() |
|||
107-P | Global tests of blood clotting during asparaginase treatment for acute lymphoblastic leukaemia. Preliminary results of the GlobALL study | Kate Burley | ![]() |
![]() |
|||
109-P | Low-dose rituximab in combination with eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. | Perla Colunga | ![]() |
![]() |
|||
110-P | A retrospective study assessing the incidence of hospital acquired thrombosis over an eight year period spanning the introduction of mandatory venous thromboembolism (VTE) risk assessment | Michelle Melly | ![]() |
![]() |
|||
112-P | Effect of extremes of body weight on efficacy and safety of rivaroxaban in the treatment of venous thromboembolism; real life experience | Deepa Arachillage | ![]() |
![]() |
|||
113-P | Missed VTE Risk Assessments at Aintree University Hospital Trust: A Retrospective Analysis | Julia Parton | ![]() |
![]() |
|||
116-P | Evaluation of a simplified procedure for EQA samples: First survey results for the point of care testing (POCT) INR EQA for CoaguChek, XS Plus & XS Pro users | Shelene Munroe-Peart | ![]() |
![]() |
|||
117-P | Commutability of samples used to assess assays for direct oral anticoagulants (DOACS): Data from UK NEQAS for Blood Coagulation multicentre studies | Ian Jenningsi | ![]() |
![]() |
|||
118-P | Point of care ddimer testing in practice: Survey results for ddimer testing performed in patient care within the United Kingdom | Lilia Brown | ![]() |
![]() |
|||
119-P | Von Willebrand factor (VWF) assays and the diagnosis of von Willebrand disease (VWD). Who follows the guidelines? | Ian Jennings | ![]() |
![]() |
|||
120-P | Continued discrepancies between protein S activity assays? | Ian Jennings | ![]() |
![]() |
|||
121-P | Identifying factors that influence the agreement between platelet function tests in patients on P2Y12-inhibitors with a high bleeding risk | Minka Vries | ![]() |
![]() |
|||
122-P | Venous thromboembolism in cardiac surgery: Comparing emergency to planned admissions over five years | Huw Rowswell | ![]() |
![]() |
|||
125-P | An audit of thromboprophylaxis and venous thromboembolism rates in myeloma patients at Kings College Hospital | Zara Sayar | ![]() |
![]() |
|||
126-P | Use of age adjusted d-dimer monitoring to assist the withdrawal of anticoagulation following unprovoked pulmonary embolism | Kathryn Musgrave | ![]() |
![]() |
|||
127-P | Is there any clinical or biological difference that distinguishes recurrence from non-recurrence after idiopathic PE? | Matthew Alley | ![]() |
![]() |
|||
132-P | Modified computer assisted strain gauge plethysmography (venometer V3) can safely decrease the need for compression ultrasound scanning in patients with suspected deep vein thrombosis | Andrew Hughes | ![]() |
![]() |
|||
133-P | The use of age-adjusted d-dimer in patients over 50 years old presenting with a suspected deep vein thrombosis can safely decrease the need for compression ultrasound scanning | Andrew Hughes | ![]() |
![]() |
|||
134-P | A survey of the management of venous thrombosis in cancer associated thrombocytopenia | Catherine Hildyard | ![]() |
![]() |
|||
136-P | Continuation of eculizumab in atypical haemolytic syndrome (aHUS) patients without renal recovery or an identified complement defect | Rebecca Shaw | ![]() |
![]() |
|||
138-P | Effects of rivaroxaban and apixaban on routine coagulation screening tests | Sean Platton | ![]() |
![]() |
|||
139-P | Evaluation of diagnostic delay in a cohort of individuals with acquired haemophilia A | Aishah Anwar | ![]() |
![]() |
|||
142-P | The relevance of placental infarction for subsequent pregnancies following stillbirth | Sarah Wharin | ![]() |
![]() |
|||
143-P | Single UK tertiary neonatal unit experience of neonatal arterial thrombosis | Jean Yong | ![]() |
![]() |
|||
156-P | The impact of TTP specialist centres on patient survival and satisfaction | Ryan Low | ![]() |
![]() |
|||
158-P | Assessment of deep venous thrombosis referrals in an ambulatory emergency care unit : A single centre study | Rodothea Amerikanou | ![]() |
![]() |
|||
159-P | The DAWN 4S VTE module - an electronic tool and record for deep vein thrombosis (DVT) assessment, diagnosis, treatment and follow up | Jane Strong | ![]() |
![]() |
|||
160-P | Validation of the use of age adjusted d-dimer cut off values to reduce the compression venous ultrasound rates in an acute ambulatory DVT service | Jane Strong | ![]() |
![]() |
|||
161-P | A snapshot of anticoagulation in a district general hospital | ruth cumber | ![]() |
![]() |
|||
162-P | Dilute Russells viper venom time potential use for the detection of apixaban and rivaroxaban predicted from interference in lupus anticoagulant testing | Sean Platton | ![]() |
![]() |
|||
166-P | Outcomes of patients treated for cancer or chemotherapy associated venous thromboembolism and effectiveness of secondary prevention | DAVID MCCLINTON | ![]() |
![]() |
|||
168-P | DOACs: Common and uncommon errors. A brief patient safety intervention and review. | Victoria Ware | ![]() |
![]() |
|||
169-P | The introduction of Laboratory based TEG testing: Could South Tees NHS Foundation Trust introduce an individualised goal-directed therapy supporting effective blood management | Daniella M Winterburn | ![]() |
![]() |
|||
177-P | Impact of adhesion molecules expression on nodal and extra-nodal involvement in chronic lymphocytic leukemia | Azza Kamel | ![]() |
![]() |
|||
180-P | Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia | Carmela Ciardullo | ![]() |
![]() |
|||
189-P | Dysregulation of CCN1 expression in conjunction with increased expression of p21CIP1 and p27KIP1 implicated in mantle cell lymphoma progression | Afak Zaidi | ![]() |
![]() |
|||
193-P | A comparison of PCR methods for the detection of MYD88 L265P mutations in a diagnostic setting | Jamal Anwar | ![]() |
![]() |
|||
196-P | Efficacy of different chemotherapy regimens in primary mediastinal large B-cell lymphoma | Inga Ilyasova | ![]() |
![]() |
|||
197-P | What is the best route for methotrexate delivery to reduce the incidence of central nervous system relapse in diffuse large B-cell lymphoma? A review of our practice at University Hospital Aintree, Liverpool | Jonathan Heseltine | ![]() |
![]() |
|||
198-P | Efficacy and safety of RCEOP chemotherapy in patients with diffuse large cell lymphoma (DLCL) not fit for anthracyclines are comparable to RCHOP | Danya Abdulwahid | ![]() |
![]() |
|||
200-P | Diagnosing light chain (AL) amyloidosis on temporal artery biopsies for suspected giant cell arteritis | Rosanna Ghinai | ![]() |
![]() |
|||
205-P | The NCRI Myeloma XI trial for newly diagnosed symptomatic multiple myeloma (NDMM); second primary malignancy (SPM) incidence when lenalidomide is used as an induction and maintenance treatment option | John Jones | ![]() |
![]() |
|||
208-P | Experience of lenalidomide use in the treatment of myeloma at North Bristol NHS Trust - increasing number of dose modifications is associated with increased overall survival | Julia Wolf | ![]() |
![]() |
|||
209-P | The addition of rituximab to CODOX-M & IVAC in first line therapy of poor risk Burkitt lymphoma (IPI 3-5) yields an excellent outcome: A phase 2 UK NCRI / Bloodwise Trial (LLR 04058) | Andrew McMillan | ![]() |
![]() |
|||
210-P | Front line therapy with R-CODOX-M & R-IVAC in poor risk diffuse large B cell lymphoma (IPI 3-5) yields a good outcome without transplantation: A phase 2 UK NCRI / Bloodwise Trial | Andrew McMillan | ![]() |
![]() |
|||
215-P | Audit of thromboprophylaxis for patients with multiple myeloma on treatment with immunomodulatory drugs | Guy Pratt | ![]() |
![]() |
|||
216-P | Intrathecal chemotherapy prophylaxis for diffuse large B cell lymphoma (DLBCL): Real-life clinical practice in the face of conflicting guidelines and a weak evidence base | Yooyun Chung | ![]() |
![]() |
|||
217-P | Is toxicity and inpatient admission time reduced with recently introduced GDP salvage chemotherapy compared to IVE and DHAP chemotherapy? A retrospective review of relapsed and refractory lymphoma patients in the Northern region of England | Jennifer Orr | ![]() |
![]() |
|||
225-P | Population-based study of patients with mantle cell lymphoma; era by era improvement in survival mediated by first-line rituximab and autologous stem cell transplantation | Komal Joshi | ![]() |
![]() |
|||
228-P | Focal segmental glomerulosclerosis: A paraneoplastic phenomenon of mantle cell lymphoma | David Sparksman | ![]() |
![]() |
|||
232-P | Subcutaneous rituximab can be safely administered without pre-medication | Samuel Burrows | ![]() |
![]() |
|||
243-P | A dramatic response to lenalidomide based chemotherapy in a patient with multiple relapsed GCB-subtype diffuse large B cell lymphoma post allogeneic stem cell transplant | Philip George | ![]() |
![]() |
|||
248-P | An update on prospective audit of rivaroxaban as prophylaxis and treatment during myeloma therapy with immunomodulatory drugs (IMiDs) at East Kent Hospitals University NHS Foundation Trust | Catherine Roughley | ![]() |
![]() |
|||
249-P | Hepatotoxicity with pegylated-asparaginase in acute lymphoblastic leukaemia is influenced by raised body mass index | Kanchana De Abrew | ![]() |
![]() |
|||
255-P | Tumour lysis risk assessment and prophylaxis for high grade lymphoma in a large university hospital - an audit against BCSH Guidelines | Emily Chernucha | ![]() |
![]() |
|||
257-P | The cost of myeloma: A gap analysis in the diagnostic work-up of multiple myeloma at Gloucestershire Hospitals NHS Foundation Trust | Marquita Camilleri | ![]() |
![]() |
|||
265-P | Nodular Lymphocyte Predominant Hodgkin Lymphoma: A retrospective review of consecutive cases managed through a single MDT in the East of England between 1999 and 2015. | Jessica Griffin | ![]() |
![]() |
|||
266-P | A single centre experience of DPACE-based therapy with lenalidomide or thalidomide /- bortezomib prior to autologous transplant in myeloma | Kanchana De Abrew | ![]() |
![]() |
|||
272-P | A retrospective review of CNS prophylaxis in diffuse large B cell lymphoma in two district | Angharad Pryce | ![]() |
![]() |
|||
273-P | The evolution of first line treatment of multiple myeloma - a retrospective review of overall survival and time to second treatment | Alice Hart | ![]() |
![]() |
|||
281-P | Assessment of DNA damage and DNA damage response and repair in dormant leukaemic cells | SAHAR ALDOSARI | ![]() |
![]() |
|||
283-P | Reduced Fas-associated phosphatase-1 expression in patients with acute myeloid leukaemia | Nahla Osman | ![]() |
![]() |
|||
290-P | T cell subsets do not alter on decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: Data from the DESTINY trial | Gemma Austin | ![]() |
![]() |
|||
292-P | Small molecule inhibitors against PI3K/Akt/mTOR and NF-kB signaling pathways as a combinatorial approach in acute myeloid leukemia treatment | Andre G Deslauriers | ![]() |
![]() |
|||
294-P | Germline heterozygous DDX41 variants account for a subset of familial myelodysplasia and acute myeloid leukaemia | Shirleny Cardoso | ![]() |
![]() |
|||
295-P | Ribosomal protein S6 dephosphorylation is a rapid broad-spectrum biomarker for therapeutic targeting of leukaemia cells | Martin Grundy | ![]() |
![]() |
|||
304-P | Prospective study of trough imatinib levels in newly diagnosed chronic myeloid leukaemia (CML) patients and its correlation with response | Charles Agbuduwe | ![]() |
![]() |
|||
309-P | Risk of cardiovascular disease (CVD) in chronic myelogenous leukemia (CML) patients from community-based oncology practices | Anna Dsouza | ![]() |
![]() |
|||
310-P | Status of persistent, grade 1/2 imatinib-related adverse events (AEs) in chronic phase chronic myeloid leukemia (CML-CP) patients after switching to dasatinib (DASPERSE/CA180-400) | Megan McNamee | ![]() |
![]() |
|||
311-P | The use of ruxolitinib in the treatment of myelofibrosis: A review of clinical practice and response in a single teaching hospital | Sara Elhag | ![]() |
![]() |
|||
312-P | Thiamine deficiency is uncommon in patients with myeloproliferative neoplasms | Natalia Curto-Garcia | ![]() |
![]() |
|||
315-P | Danazol as first-line therapy for myelodysplastic syndromes | Perla Colunga | ![]() |
![]() |
|||
329-P | CNS demyelination in patients on nilotinib treatment for CML | A Pryce | ![]() |
![]() |
|||
331-P | A review of new diagnoses of haematological malignancies within the Leicestershire, Northamptonshire and Rutland region | Lucinda Sanders | ![]() |
![]() |
|||
332-P | Implementation of high throughput sequencing in an integrated laboratory: Experience from the Haematological Malignancy Diagnostic Service (HMDS) | Jan Taylor | ![]() |
![]() |
|||
340-P | Unlocking the Potential of Coagulation Clinical Nurse Specialists | Sinead Brookman | ![]() |
![]() |
|||
344-P | The impact of immune thrombocytopenia on health-related quality of life in children | Charlotte Colam | ![]() |
![]() |
|||
348-P | Presentation, course and outcome of langerhans cell histiocytosis in children | Fauzia khan | ![]() |
![]() |
|||
349-P | Leukostasis and tumor lysis syndrome in childrens leukaemia admitted to an intensive care unit | diana mota | ![]() |
![]() |
|||
350-P | Review of an internal quality assurance programme for transcranial doppler (TCD) screening in children with sickle cell disease. Experiences from Barts Health NHS Trust | Banu Kaya | ![]() |
![]() |
|||
357-P | Treating sickle cell acute pain crisis at a busy London emergency department | Rodothea Amerikanou | ![]() |
![]() |
|||
358-P | Investigation of Anaemia in Patients Admitted to a Medicine of the Elderly Unit | Angus Killean | ![]() |
![]() |
|||
361-P | Fat embolism syndrome in 3 patients with sickle cell disease | Angela Collins | ![]() |
![]() |
|||
366-P | Hydroxyurea and sickle cell disease: Do we need to reach the maximally tolerated dose (MTD)? | Wesam AL-SAKKAF | ![]() |
![]() |
|||
375-P | A life-threatening autoimmune hemolytic anemia in a patient with newly-diagnosed pulmonary sarcoidosis | Angeliki Ntineri | ![]() |
![]() |
|||
377-P | Decreased SOD2 mRNA levels in peripheral blood cells from steady-state sickle cell disease patients | I.A. Armenis | ![]() |
![]() |
|||
379-P | Annual review of transfusion targets in regularly transfused paediatric and adult sickle cell patients. Experiences from Barts Health NHS Trust | Kaya Banu | ![]() |
![]() |
|||
381-P | Seroepidemiology of hepatitis B, C & HIV among blood donors in Jos, North-Central Nigeria | A. Michael ONOJA | ![]() |
![]() |
|||
382-P | Public involvement in clinical research: Lessons from a cluster-randomised trial | Stephen Hibbs | ![]() |
![]() |
|||
383-P | Sustained effect on compliance with transfusion guidelines of a combination of direct feedback about practice and an electronic decision support process | Juliet Smith | ![]() |
![]() |
|||
384-P | A descriptive single centre experience of the management and outcome of maternal alloantibodies in pregnancy | Natalie Heeney | ![]() |
![]() |
|||
385-P | The impact of the implementation of an electronic prescribing system on the use of single unit transfusions in an acute haematology ward | Juliet Smith | ![]() |
![]() |
|||
389-P | Changing patterns of off-licence use of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of major haemorrhage | Jennifer Orr | ![]() |
![]() |
|||
391-P | A red cell dosage calculator could promote single unit red cell transfusion, prevent over-transfusion and reduce red cell usage | Sharran Grey | ![]() |
![]() |
|||
392-P | Optimisation of Preoperative Anaemia in Patients Undergoing Elective Cardiac Surgery | NADIA BLUNT | ![]() |
![]() |
|||
394-P | Tertiary Neonatal Single Centre Experience of Fresh Frozen Plasma Transfusion - an Audit of Current Practice | Sarah Dillon | ![]() |
![]() |
|||
400-P | Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients | Claudia Monica Gorcea | ![]() |
![]() |
|||
401-P | Is there any difference in line infection rates between Hickmann and internal jugular/subclavian central lines in stem cell transplant patients? | Claire Stockdale | ![]() |
![]() |
|||
404-P | Donors who are heavier than their recipient, male, have a BMI 30 or are younger provide the best chance of meeting the requested cell dose for PBSC transplantation | Annelies Billen | ![]() |
![]() |
|||
406-P | Outcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation (non-transplant consolidation NTC) therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) | John Ashcroft | ![]() |
![]() |
|||
407-P | Donor cell t(8;21) AML after allogeneic unrelated donor hematopoietic stem cell transplantation for infant ALL | SABET IMAN | ![]() |
![]() |
|||
412-P | An audit of stopping antifungal prophylaxis post allogeneic stem cell transplantation. | POOJA PAREKH | ![]() |
![]() |
|||
527-P | Identifying and prioritising treatment uncertainties in blood transfusion through the James Lind Alliance | Mike Murphy | ![]() |
![]() |
18-21 April 2016 Glasgow
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|